Drs. Pranita Tamma (@pranita_tamma) and Sam Aitken (@OncIDPharmd) are BACK on the podcast this week with Dr. Erin McCreary (@ErinMcCreary) to discuss IDSA guidance on AmpC producers, carbapenem-resistant Acinetobacter baumanii, and Stenotrophomonas as part of our series on gram-negative bacteria. Listen as the panelists navigate the hot mess that is the CRAB treatment landscape, have a minocycline appreciation moment (we stan for Steno Sam!), and throw down some bar trivia in an "I Feel Nerdy" segment that you don't want to miss.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References

1. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa) - PubMed (nih.gov)
2. Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections - PubMed (nih.gov)
3. An Overview of the Treatment of Less Common Non-Lactose-Fermenting Gram-Negative Bacteria
4. Alterations of the Oral Microbiome and Cumulative Carbapenem Exposure Are Associated With Stenotrophomonas maltophilia Infection in Patients With Acute Myeloid Leukemia Receiving Chemotherapy